KRAS and familial pancreatic carcinoma: We decided to use CR-1-31-B, a synthetic rocaglate with more favorable pharmacokinetic properties than RocA, which has already demonstrated antitumor activity in mouse models, e.g., in KRAS-driven pancreatic cancer (38).